Searched for
MOLNUPIRAVIR MSD
Molnupiravir reduced Covid-linked hospitalisation by over 65%: StudyThe Phase III trial results of Hetero's Movfor (Molnupiravir), presented at the Conference on Retroviruses and Opportunistic Infections (CR...- Phase III trials of COVID drug Movfor show positive results, says HeteroThe results, presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12...
- Natco Pharma signs pact with MPP to sell Molnupiravir capsulesNatco Pharma has signed a non-exclusive license agreement with the Medicines Patent Pool (MPP), Switzerland to manufacture and sell Molnupi...
- Merck says no safety concerns observed in molnupiravir phase-3 trial, shared relevant data with DCGIMerck Sharp & Dohme (MSD) on Friday said its COVID antiviral molnupiravir has cut the risk of hospitalization or death in Phase 3 clinical ...
- Aurobindo Pharma launches COVID-19 drug Molnupiravir in IndiaMolnupiravir is for treatment of adult patients hospitalised with COVID-19, under certain conditions, a press release from the city-based d...
- Mankind Pharma set to roll out cheapest coronavirus drugThe full treatment of Molulife (brand name) is expected to cost ₹1,400, RC Juneja, chairman of Mankind Pharma, told ET. The brand is expect...
- Companies race to make COVID antiviral drug molnupiravir available in pharmaciesDrug maker Cipla said it will soon make molnupiravir capsules available at all leading pharmacies and Covid treatment centers across the co...
- Torrent Pharma to launch Molnupiravir under Molnutor brand name to treat COVID-19Torrent Pharmaceuticals on Tuesday said it will launch MSD and Ridgeback's molnupiravir under the brand name Molnutor in India for the trea...
- Sun Pharma gets DCGI nod to market molnupiravir for COVID-19 treatmentEarlier this year, the Mumbai-based drug major had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply ...
- USFDA okays Merck's Covid Drug for use in high-risk casesThe USFDA also said molnupiravir should be given to those for whom alternative Covid-19 treatment options authorised by it are not accessib...
- USFDA approves COVID antiviral pill molnupiravir for emergency useThe USFDA also said the drug should be given for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or cl...
- COVID antiviral drug Molnupiravir efficacy against hospitalization or death drops to 30% compared to placebo groupThe analysis of latest data on efficacy is much less than the previous interim analysis announced by the company which was based on data fr...
- Panel to meet today to take up applications seeking nod for MolnupiravirThe firms whose applications that will be taken up are Dr Reddy's Laboratories which has filed for approval in a consortium with five other...
- Sun Pharma says gearing up to launch COVID drug molnupiravirThe company said the Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COV...
- With UK nod, Merck drug becomes world's 1st pill for Covid treatmentThe MHRA recommended the use of Covid-19 drug molnupiravir as soon as possible following a positive Covid-19 test and within five days of s...
- UK drug regulatory approves COVID antiviral drug MolnupiravirThe risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease. MHRA recommended the use of Molnupiravir as s...
- MSD enters pact with UN-backed MPP to license COVID drug molnupiravir in 105 countries including IndiaUnder the terms of the agreement, MPP will be permitted to further license non-exclusive sub-licences to manufacturers and diversify the ma...
- Domestic pharma majors join hands for clinical trial of Molnupiravir for COVID-19 treatmentThe clinical trial will be conducted for the treatment of mild COVID-19 in an outpatient setting and is expected to take place between June...
- MSD in talks with Medicines Patent Pool for additional licenses for molnupiravirMSD entered into a voluntary licensing agreement with five Indian drug makers including Sun Pharma, Cipla, Dr. Reddy’s, Emcure and Hetero f...
- MSD to sign licensing pacts with 5 Indian drug firms for oral drug candidate for COVID-19MSD has decided to enter into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generic manufactur...
Load More
